Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Other · France
Industry association · Switzerland
Declared costs: €200K+ a year · in the register since 2018
Transitional provisions for certain medical devices and in vitro diagnostic medical devices · Implementing rules regarding requirements to be met by notified bodies
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
MD-EX · filed 13 Jan 2023 · source
Dear, First I want to thank you to permit to give our feedback. Below some questions/ comments : - Harmonization for qualification of product reviewer and recognition at European Level RDM 2017/745 Annex VII §3.2.5 Criteria for qualification of product reviewer is not sufficiently detailed in RDM 2017/745 and subject to the interpretation and not harmonization between NB regarding qualification.
Medtech & Pharma Platform Association · filed 18 Jan 2023 · source
The Medtech & Pharma Platform Association (MPP) is writing to you to share its views on the European Commissions proposal regarding the transition periods of the Medical Devices Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR). Overall, the MPP supports and welcomes the proposal, which is crucial to ensure the continued supply of products to patients.
MD-EX · filed 21 Jan 2026 · source
I fully share the objective of this revision. It is indeed essential to adapt the regulatory framework in order to enable companies, particularly SMEs, to cope with requirements that can sometimes be disproportionate, with unpredictable timelines and an administrative burden that has become difficult to sustain.
Medtech & Pharma Platform Association · filed 23 Jan 2026 · source
The Medtech & Pharma Platform Association (MPP) welcomes the proposed EU Implementing Regulation establishing harmonised quality management and procedural requirements for conformity assessment activities performed by notified bodies. We consider the introduction of requirements for reliable quotations, predictable timelines, and transparent monitoring of both timelines and costs to be a positive step.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.